Your email has been successfully added to our mailing list.

×
0 0 0 0.00638977635782748 0.0143769968051118 0.000798722044728417 0.000798722044728417 0.000798722044728417
Stock impact report

Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform [Seeking Alpha]

Cidara Therapeutics, Inc. (CDTX) 
Last cidara therapeutics, inc. earnings: 3/4 05:55 am Check Earnings Report
US:NASDAQ Investor Relations: ir.cidara.com
Company Research Source: Seeking Alpha
Following a considerable private placement and re-acquisition of CD388 from Janssen, CDTX is well funded to start and complete a ph2b trial. Cidara Therapeutics no longer expects any milestone/royalty revenue but will be able to raise funds from a much stronger position following a positive ph2b trial for CD388. Thesis update In my prior coverage , I recommended buying Cidara Therapeutics, Inc. NASDAQ: CDTX ) following the validation of CD388 potential by Janssen's decision to keep CD388 rights. In that coverage, I made it clear that "I see CDTX as a Recommended For You Recommended For You About CDTX Stock Related Stocks Trending Analysis Trending News Show less Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
CDTX alerts

from News Quantified
Opt-in for
CDTX alerts

from News Quantified